A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Exclusion Criteria

• •Mucosal or ocular melanoma.
• •Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment with chronic systemic steroid therapy or any other form of immunosuppressive therapy within the past 2 years.
• •Clinically significant cardiovascular diseases.
• •History of thromboembolic or cerebrovascular events ≤12 weeks prior to randomization.
• •History or current evidence of RVO or current risk factors for RVO.
• •Concurrent neuromuscular disorder that is associated with the potential of elevated CK.
• •Active bacterial, fungal, or viral infection requiring systemic therapeutic treatment within 2 weeks prior to randomization.
• •Current non-infectious pneumonitis/interstitial lung disease or history of noninfectious pneumonitis/interstitial lung disease requiring steroids.
• •Prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases.
• •Participants who permanently discontinued prior anti-PD-1 therapy due to toxicity or will be unable to tolerate combination therapy based on investigator judgement are excluded.
• •Prior treatment with ipilimumab; prior combined immunotherapy blockade with anti-PD-1/L-1; prior treatment with a BRAFi and/or MEKi; or previous administration of an investigational anti-cancer agent for the adjuvant or first-line treatment of melanoma prior to randomization.